Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group Study

Cancer

Volumn 107, Issue 6, 2006, Pages 1280-1286

  Covens, Allan ^a,d   Filiaci, Virginia L ^b   Burger, Robert A ^c   Osborne, Raymond ^d   Chen, M Dwight ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e Women's Cancer Center   (United States)

Author keywords

Dactinomycin; Gestational trophoblastic disease; Salvage Chemotherapy

Indexed keywords

ANTIEMETIC AGENT; CHORIONIC GONADOTROPIN; DACTINOMYCIN; DEXAMETHASONE; METHOTREXATE; SEROTONIN 3 ANTAGONIST;

ACNE; ADULT; ALOPECIA; ARTICLE; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG PULSE THERAPY; DRUG TOLERABILITY; DRY SKIN; EXTRAVASATION; FEMALE; FLUSHING; HEMATOMA; HUMAN; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SKIN TOXICITY; TREATMENT FAILURE; TROPHOBLASTIC TUMOR; VOMITING;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CHORIONIC GONADOTROPIN; DACTINOMYCIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; NAUSEA; NEUTROPENIA; PREGNANCY; PULSE THERAPY, DRUG; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME; VOMITING;

EID: 33749004802     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22118     Document Type: Article

References (23)

1. Goldstein DP, Winig P, Shirley RL. Actinomcyin D as initial therapy of gestational trophoblastic disease. Obstet Gynecol. 1972;39:341-345.
2. Ross GT, Goldstein DP, Hertz R, Lipsett MB, Odell WD. Sequential use of methotrexate and actinomycin D in the treatment of metastatic choriocarcinoma and related trophoblastic diseases in women. Am J Obstet Gynecol. 1965;93:223-229.
3. Twiggs LB. Pulse actinomycin D scheduling in non-metastatic gestational trophoblastic neoplasia: cost-effective chemotherapy. Gynecol Oncol. 1983;16:190-195.
4. Petrilli ES, Morrow CP. Actinomycin D toxicity in the treatment of trophoblastic disease: a comparison of the five day course to single dose administration. Gynecol Oncol. 1980;9:18-22.
5. Petrilli ES, Twiggs LB, Blessing JA, et al. Single dose actinomycin D treatment for nonmetastatic gestational trophoblastic disease. Cancer. 1987;60:2173-2176.
6. Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer. 1975;36:863-866.
7. Schlaerth JB, Morrow CP, Nalick RH, et al. Single dose actinomycin D in the treatment of postmolar trophoblastic disease. Gynecol Oncol 1984;19:53-56.
8. McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992-2000. J Clin Oncol 2002;20:1838-1844.
9. Berkowitz BJ, Goldstein DP, Bernstein BFA. Ten year experience with methotrexate and folinic acid rescue as primary therapy for gestational trophoblastic disease. Gynecol Oncol. 1986;23:111-118.
10. Bagshawe KD, Dent J, Newlands ES, Begent RHJ, Rustin GJS. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumors. Br J Obstet Gynecol. 1989;96:795-802.
11. Homesley HD, Blessing JA, Rottenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol. 1988;72:413-418.
12. Lurain JR, Elfstrand E. Single agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumours. Am J Obstet Gynecol. 1995;172:574-579.
13. Quinn M, Murray M, Friedlander S, et al. EMA/CO in high risk gestational trophoblastic disease-the Australian experience. Aust NZ J Obstet Gynaecol 1994;34:90-92.
14. Simon R. Optimal two-stage trial design for phase II trials. Control Clin Trials. 1989;10:1-10.
15. Chen TT, Ng T. Optimal flexible designs in phase II clinical trials. Stat Med. 1998;17:2301-2312.
16. Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics. 1985;41:741-744.
17. Cole LA. Phantom hCG and phantom choriocarcinoma. Gynecol Oncol. 1998;71:325-329.
18. Rustin GJS, Newlands ES, Lutz JM, Holden S, Short D. Combination but not single agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumours. J Clin Oncol. 1996;14:2769-2773.
19. Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol. 1994;54:76-79.
20. Kohorn EI. Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia. Int J Gynecol Cancer. 1996;6:279-285.
21. Kohorn EI. Evaluation of the criteria used to make the diagnosis of nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol. 1983;48:139-147.
22. Dobson LS, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide, and dactinomycin) as first line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second line therapy for low risk disease. Br J Cancer. 2000;82:1547-1552.
23. Kohorn EI. Is lack of response to single agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? Gynecol Oncol. 2002;85:36-39.